+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

VPS35 mutations in Parkinson disease



VPS35 mutations in Parkinson disease



American Journal of Human Genetics 89(1): 162-167



The identification of genetic causes for Mendelian disorders has been based on the collection of multi-incident families, linkage analysis, and sequencing of genes in candidate intervals. This study describes the application of next-generation sequencing technologies to a Swiss kindred presenting with autosomal-dominant, late-onset Parkinson disease (PD). The family has tremor-predominant dopa-responsive parkinsonism with a mean onset of 50.6 ± 7.3 years. Exome analysis suggests that an aspartic-acid-to-asparagine mutation within vacuolar protein sorting 35 (VPS35 c.1858G>A; p.Asp620Asn) is the genetic determinant of disease. VPS35 is a central component of the retromer cargo-recognition complex, is critical for endosome-trans-golgi trafficking and membrane-protein recycling, and is evolutionarily highly conserved. VPS35 c.1858G>A was found in all affected members of the Swiss kindred and in three more families and one patient with sporadic PD, but it was not observed in 3,309 controls. Further sequencing of familial affected probands revealed only one other missense variant, VPS35 c.946C>T; (p.Pro316Ser), in a pedigree with one unaffected and two affected carriers, and thus the pathogenicity of this mutation remains uncertain. Retromer-mediated sorting and transport is best characterized for acid hydrolase receptors. However, the complex has many types of cargo and is involved in a diverse array of biologic pathways from developmental Wnt signaling to lysosome biogenesis. Our study implicates disruption of VPS35 and retromer-mediated trans-membrane protein sorting, rescue, and recycling in the neurodegenerative process leading to PD.

(PDF emailed within 0-6 h: $19.90)

Accession: 036149129

Download citation: RISBibTeXText

PMID: 21763482

DOI: 10.1016/j.ajhg.2011.06.001


Related references

Screening for VPS35 mutations in Parkinson's disease. Neurobiology of Aging 33(4): 838.E1-5, 2012

Contributions of VPS35 mutations to Parkinson's Disease. Neuroscience 2019, 2019

VPS35 and EIF4G1 mutations are rare in Parkinson's disease among Indians. Neurobiology of Aging 34(10): 2442.E1-3, 2014

Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 78(18): 1449-1450, 2012

Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Human Molecular Genetics 23(17): 4621-4638, 2015

An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson's disease. Neuroscience Letters 610: 135-138, 2016

EIF4G1 R1205H and VPS35 D620N mutations are rare in Parkinson's disease from South Africa. Neurobiology of Aging 35(2): 445.E1-3, 2014

VPS35 Asp620Asn and EIF4G1 Arg1205His mutations are rare in Parkinson disease from southwest China. Neurobiology of Aging 34(6): 1709.E7-8, 2013

Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil. Neuroscience Letters 635(): 67-70, 2016

The VPS35 gene and Parkinson's disease. Movement Disorders 28(5): 569-575, 2014

VPS35: A new player in Parkinson's disease. Movement Disorders 26(10): 1803-1803, 2011

Deciphering the role of VPS35 in Parkinson's disease. Journal of Neuroscience Research: -, 2018

VPS35, the Retromer Complex and Parkinson's Disease. Journal of Parkinson's Disease 7(2): 219-233, 2017

Frequency of the D620N mutation in VPS35 in Parkinson disease. Archives of Neurology 69(10): 1360-1364, 2013

Linking the VPS35 and EIF4G1 pathways in Parkinson's disease. Neuron 85(1): 1-3, 2015